Back to results
US 8,911,991 B2Granted
Multi-antigen vectors of melanoma
AssigneeSanofi Pasteur Limited
InventorsNeil Berinstein, James Tartaglia, Mark Parrington, Dennis L. Panicali, Linda Gritz
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.
Claims1
A dosage unit comprising at least first and second separate compositions, the first composition containing an ALVAC(2) expression vector encoding CD80 (SEQ ID NO:
- 14), ICAM-1 (SEQ ID NO:
- 16), LFA-3 (SEQ ID NO:
- 15), gp100M (SEQ ID NO:
- 10), MART-1 (SEQ ID NO:
- 11), and the MAGE1/3 minigene (nucleotides 8111-8254 of SEQ ID NO.:5), and the second composition comprising an ALVAC(2) expression vector encoding CD80 (SEQ ID NO:
- 14), ICAM-1 (SEQ ID NO:
- 16), LFA-3 (SEQ ID NO:
- 15), TRP-2 (SEQ ID NO:
- 8, and NY-ESO-1 (SEQ ID NO:
- 7), wherein administration of the compositions to a host results in an immune response in the host against gp100, MART-1 and NY-ESO-1.
7 more elements
Dependencies are inferred from the claim text.